Diabetes, Vol 45, Issue 12 1792-1797, Copyright © 1996 by American Diabetes Association

ARTICLES

Mechanisms of sulfonylurea's stimulation of insulin secretion in vivo: selective amplification of insulin secretory burst mass

NK Porksen, SR Munn, JL Steers, O Schmitz, JD Veldhuis and PC Butler
Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota, USA.

Although sulfonylureas enhance insulin secretion, it is unknown whether these hypoglycemic chemicals stimulate insulin secretion through the augmentation of the pulsatile or basal modes of insulin release. Enhanced pulsatile insulin could occur in turn through amplification of the burst mass or an increase in burst frequency. To address the mechanism of sulfonylurea action, we employed a recently validated canine model with a portal vein sampling catheter and flow probe to measure pulsatile insulin secretion in vivo directly in response to tolbutamide infusion or ingestion. After a 16-h fast, seven dogs were studied in the postabsorptive basal state and during a tolbutamide (0.2 mg/min) infusion when their plasma glucose concentrations were clamped at euglycemia. Insulin concentrations in the carotid artery (basal vs. tolbutamide, 85 +/- 12 vs. 325 +/- 66 pmol/l; P < 0.01) and portal vein (basal vs. tolbutamide, 345 +/- 55 vs. 1,288 +/- 230 pmol/l; P < 0.01) increased during tolbutamide infusion, but the portal vein plasma flow did not change. Increased plasma insulin concentrations were achieved by a fourfold increase in the total insulin secretion rate (2.3 +/- 0.2 to 9.4 +/- 1.9 pmol x kg(-1) x min(-1); basal vs. tolbutamide, P < 0.01). The augmented total insulin secretion was achieved mechanistically via a marked and selective increase in the insulin secretory burst mass (basal vs. tolbutamide, 266 +/- 64 vs. 817 +/- 144 pmol/pulse; P < 0.01), with no change in portal-vein insulin pulse frequency (basal vs. tolbutamide, 10.1 +/- 0.6 vs. 11.1 +/- 0.8 pulses/h; P = 0.3). Oral (250 mg) tolbutamide also magnified the endogenous insulin secretion rate by the preferential amplification of the secretory pulse mass (basal vs. tolbutamide, 167 +/- 37 vs. 362 +/- 50 pmol/pulse; P < 0.01). Neither the infusion nor the ingestion of tolbutamide changed the calculated clearance rates of endogenously secreted insulin. We conclude that sulfonylurea (tolbutamide) induced insulin secretion in vivo is achieved by the highly selective amplification of insulin secretory burst mass with no change in basal insulin release or the frequency of the beta-cell-network pacemaker.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. J. Meier, L. L. Kjems, J. D. Veldhuis, P. Lefebvre, and P. C. Butler Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes, April 1, 2006; 55(4): 1051 - 1056. [Abstract] [Full Text] [PDF]

				R. A. Ritzel, J. D. Veldhuis, and P. C. Butler The mass, but not the frequency, of insulin secretory bursts in isolated human islets is entrained by oscillatory glucose exposure Am J Physiol Endocrinol Metab, April 1, 2006; 290(4): E750 - E756. [Abstract] [Full Text] [PDF]

				J. J. Meier, J. D. Veldhuis, and P. C. Butler Pulsatile Insulin Secretion Dictates Systemic Insulin Delivery by Regulating Hepatic Insulin Extraction In Humans Diabetes, June 1, 2005; 54(6): 1649 - 1656. [Abstract] [Full Text] [PDF]

				N. Porksen, T. Grofte, J. Greisen, A. Mengel, C. Juhl, J. D. Veldhuis, O. Schmitz, M. Rossle, and H. Vilstrup Human insulin release processes measured by intraportal sampling Am J Physiol Endocrinol Metab, March 1, 2002; 282(3): E695 - E702. [Abstract] [Full Text] [PDF]

				N. Porksen, M. Hollingdal, C. Juhl, P. Butler, J. D. Veldhuis, and O. Schmitz Pulsatile Insulin Secretion: Detection, Regulation, and Role in Diabetes Diabetes, February 1, 2002; 51(90001): S245 - 254. [Abstract] [Full Text] [PDF]

				S. H. Song, L. Kjems, R. Ritzel, S. M. McIntyre, M. L. Johnson, J. D. Veldhuis, and P. C. Butler Pulsatile Insulin Secretion by Human Pancreatic Islets J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 213 - 221. [Abstract] [Full Text] [PDF]

				C. B. Juhl, N. Porksen, S. M. Pincus, A. P. Hansen, J. D. Veldhuis, and O. Schmitz Acute and Short-Term Administration of a Sulfonylurea (Gliclazide) Increases Pulsatile Insulin Secretion in Type 2 Diabetes Diabetes, August 1, 2001; 50(8): 1778 - 1784. [Abstract] [Full Text] [PDF]

				S. J. Vore, E. D. Aycock, J. D. Veldhuis, and P. C. Butler Anesthesia rapidly suppresses insulin pulse mass but enhances the orderliness of insulin secretory process Am J Physiol Endocrinol Metab, July 1, 2001; 281(1): E93 - E99. [Abstract] [Full Text] [PDF]

				R. Ritzel, M. Schulte, N. Pørksen, M. S. Nauck, J. J. Holst, C. Juhl, W. März, O. Schmitz, W. H. Schmiegel, and M. A. Nauck Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance Diabetes, April 1, 2001; 50(4): 776 - 784. [Abstract] [Full Text]

				N. Porksen, C. Juhl, M. Hollingdal, S. M. Pincus, J. Sturis, J. D. Veldhuis, and O. Schmitz Concordant induction of rapid in vivo pulsatile insulin secretion by recurrent punctuated glucose infusions Am J Physiol Endocrinol Metab, January 1, 2000; 278(1): E162 - E170. [Abstract] [Full Text] [PDF]